From biomarkers in oncology and developments in clinical trials, through to fully personalised cancer treatments and new therapeutic interventions, SMi's Cancer Vaccines conference will gather an array of immuno-oncology experts from around the world to share their knowledge on advancing cancer immuno-therapies when it returns to London next month.

Conference Highlights Include:

  • A focus on immunotherapies: Some of the topics discussed on immunotherapy include multi-model cancer immunotherapy, oncolytic virotherapy, immune response in DNA vaccinations and gene editing for immunotherapy.
  • Personalised RNA immunology: Dr Kreiter recently took part in the pioneering development of actively personalized cancer vaccination. His presentation entitled: RNA - Vaccinology: From Ware-Houses to Actively Personalized Cancer Vaccines, will discuss simulating tumour-specific antigen recognition with a focus on epitope design of multi-antigen tumour vaccines and neo-antigens. His interview is available to read in the event download centre.
  • A GSK Vaccines case study: Recent research has enabled the design of adjuvants which can optimise and boost the quality of a vaccine. Hear more on advancing the next generations of adjuvants in a presentation by the Global Head of Vaccine Chemistry and Formulation from GSK Vaccines, Derek O'Hagan. The presentation will explore the impact of delivery on adjuvants with a focus on formulation and particle size.
  • Drinks Reception: Lead sponsors Northwest Biotheraputics will host a networking drinks reception on the evening of Day One. Some of those who have confirmed attendance at the event include: Biosafe SA, Boehringer Ingelheim, Exicure Inc, Immunicum, Intellicyt, National Cancer Institute, Northwest Biotherapeutics Inc, Plymouth University, Roche, Shionogi Limited, St Georges Hospital Medical School, Theravectys, TRON Translational Oncology Mainz and University Of Pennsylvania

Already creating a buzz in the industry, here's what some of the attendees said about what presentations they were looking forward to hearing at Cancer Vaccines 2015.

"All of them! But in particular the provocative talk that will be given by Michael G. Hanna, Jr. Founder & Chairman Emeritus, Vaccinogen, Inc" - Dr. Stéphanie McArdle, Senior Research Scientist in Tumour Immunology, Nottingham Trent University

"The session on RNA vaccine, because I believe it is very promising technology to induce a powerful CD8 T cell response." - Ugo D'oro, Head of Immunology, GSK Vaccines

"..getting the big pharma viewpoint on combination immuno-oncology. I'm also keen to hear about the immuno-oncologists' current opinion regarding individualised cellular cancer immunotherapy." - Thomas Felzmann, Associate Professor of Immunology and CEO, Activartis Biotech GmbH

"Since the program is very comprehensive and picks up the hot topics it is hard to choose. For sure I am looking forward to the talks addressing tumor heterogeneity and combination therapies." - Sebastian Kreiter, VP of Immunotherapy, BioNTech RNA Pharmaceuticals

For further details, visit the website at CancerVaccinesEvent.com

Interviews with key speakers, are available to read in the event download centre

Cancer Vaccines 2015
New frontiers in targeted immuno-therapies to achieve sustained immune response
16 - 17 Sept 2015
Marriott Regents Park, London, UK
CancerVaccinesEvent.com

Sponsored by Northwest Biotherapeutics and Intellicyt